Jose Benitez, MD
Family Medicine · Coventry, RINPI 1962530691
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,399 and has fallen 84.0% since, to $224 in 2025.
Across 83 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$370
- Pfizer$314
- AstraZeneca$205
- Johnson & Johnson$162
- Sanofi-aventis U.S. LLC$130
- Galderma Laboratories, L.p.$124
- plus $907 from 19 others
What the payments were for
- Food & beverage$2,19499%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 15 | $370 |
| Pfizer | 10 | $314 |
| AstraZeneca | 7 | $205 |
| Johnson & Johnson | 3 | $162 |
| Sanofi-aventis U.S. LLC | 2 | $130 |
| Galderma Laboratories, L.p. | 1 | $124 |
| Novo Nordisk | 6 | $122 |
| Otsuka America Pharmaceutical, Inc. | 1 | $99 |
| Scilex Pharmaceuticals Inc. | 4 | $69 |
| Daiichi Sankyo Inc. | 4 | $68 |
| Boehringer Ingelheim | 3 | $61 |
| GSK | 3 | $58 |
| AbbVie(2 entities) | 3 | $55 |
| Amgen | 2 | $50 |
| Astellas Pharma US Inc | 3 | $50 |
| Napo Pharmaceuticals Inc | 1 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Merck | 2 | $26 |
| Novartis | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$242
- INVOKANA$125
- NUEDEXTA$125
- SOLIQUA 100/33$114
- FARXIGA$112
How this compares
$2,212 in reported general payments places this provider in the 80th percentile of 222 family medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 798 | $218,798 |
| XifaxanRifaximin | 42 | $78,395 |
| NuplazidPimavanserin Tartrate | 28 | $65,592 |
| XareltoRivaroxaban | 220 | $53,289 |
| JardianceEmpagliflozin | 196 | $52,765 |
| RexultiBrexpiprazole | 51 | $36,124 |
| TrulicityDulaglutide | 38 | $28,272 |
| TradjentaLinagliptin | 105 | $26,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $25,702 |
| Invega SustennaPaliperidone Palmitate | 12 | $21,960 |
| Atorvastatin Calcium | 943 | $19,817 |
| Mirtazapine | 482 | $14,514 |
| Trazodone Hcl | 845 | $14,182 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,301 |
| SantylCollagenase Clostridium Hist. | 30 | $12,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $314 | $218,798798 claims |
| Boehringer IngelheimJardiance, Tradjenta | $61 | $78,774301 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $162 | $75,250232 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $58 | $44,90990 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99 | $36,12451 claims |
| AstraZenecaBreztri Aerosphere | $205 | $10,80322 claims |
| NovartisEntresto | $20 | $9,41327 claims |
| MerckJanuvia | $26 | $8,04331 claims |
| AbbVieRestasis | $55 | $5,75916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 family medicine providers in Rhode Island.
Other family medicine in Coventry
- Daniel CollinsCoventry$5K
- Elena KwetkowskiCoventry$1K
- Gina la ProvaCumberland$778K
- Wilfredo Giordano-PerezJohnston$351K
- Martin MinerProvidence$124K
- Frank la FaziaWest Warwick$19K
- Jamiel AmbradWakefield$18K
- Jason AustinJohnston$15K
- Mary SutterPawtucket$13K
- Abdul Rahman Al HoutSmithfield$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.